About Behçet’s Disease

Behçet’s Disease is a rare, chronic, multisystem inflammatory disorder¹

Behçet’s Disease, also referred to as Behçet’s Syndrome, is classified as a variable vessel vasculitis.¹

• Multiple systems can be affected by BD, but it is often characterized by recurrent oral ulcers accompanied by lesions in other organ systems¹
• The International Study Group (ISG) criteria can be used to diagnose BD by the presence of recurrent oral ulceration plus at least 2 of the following: recurrent genital ulceration, eye lesions, skin lesions, or a positive result on pathergy testing²

A diagnosis of BD typically takes approximately 5 years from the onset of manifestations³

Recurrent oral ulcers are the hallmark manifestation of BD⁵

Oral ulcers can be bothersome and painful^6,7

• Present in 98% of patients diagnosed with BD^3,4
• Recurrent oral ulcers in BD can crop, be painful, and scar^4,8
• Diagnosis of BD with recurrent oral ulcers is complicated by a number of possible differential diagnoses, such as aphthous stomatitis or inflammatory bowel disease, among others⁹

Otezla is the first and only FDA-approved systemic therapy for oral ulcers associated with BD¹²

• In BD, the efficacy of Otezla^® (apremilast) was demonstrated based on the number and pain of oral ulcers
• The most commonly reported adverse reactions (≥10%) for Otezla were diarrhea, nausea, headache, and upper respiratory tract infection

An oral, non-biologic systemic treatment for patients with oral ulcers associated with Behçet’s Disease¹²